Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6449
+0.00380.59%
Pre-market: 0.65250.0076+1.18%04:01 EDT
Volume:9.49M
Turnover:6.07M
Market Cap:156.71M
PE:-0.86
High:0.6586
Open:0.6500
Low:0.6191
Close:0.6411
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.86
T/O Rate:4.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-15.08
PE(LYR):-0.36

Loading ...

Outlook Therapeutics Prices Offering of Common Shares

MT Newswires Live
·
May 29

Outlook to sell 8.54M shares at 58.55c in registered direct offering

TIPRANKS
·
May 29

Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share

Reuters
·
May 29

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
May 29

Outlook Therapeutics director Yezan Munther Haddadin acquires 34,000 common shares worth $14,960

Reuters
·
May 28

Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520

Reuters
·
May 28

BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment

Reuters
·
May 26

Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava

TIPRANKS
·
May 26

Outlook Therapeutics Inc - to Resubmit Ons-5,010/Lytenava Bla in June 2026

THOMSON REUTERS
·
May 26

Outlook Therapeutics Inc - FDA Finds Substantial Evidence of Effectiveness for Lytenava in Namd

THOMSON REUTERS
·
May 26

Outlook Therapeutics says FDA grants appeal on Lyt​enava effectiveness in nAMD review

Reuters
·
May 26

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

GlobeNewswire
·
May 26

Outlook Therapeutics Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
May 18

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Outlook Therapeutics Q2 adjusted EPS misses analyst expectations

Reuters
·
May 16

Outlook Therapeutics Q2 Adjusted EPS USD -0.16

THOMSON REUTERS
·
May 16

Outlook Therapeutics Inc - Completes FDA Dispute Resolution Meeting for Ons-5010; Decision Expected in May 2026

THOMSON REUTERS
·
May 16

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 16

BRIEF-Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC Filing

Reuters
·
May 14

Outlook Therapeutics Inc - Enters Atm Offering Agreement With H.c. Wainwright for up to $100 Mln - SEC Filing

THOMSON REUTERS
·
May 14